Ascend: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia

  1. Ghia, P.
  2. Pluta, A.
  3. Wach, M.
  4. Lysak, D.
  5. Kozak, T.
  6. Simkovic, M.
  7. Kaplan, P.
  8. Kraychok, I.
  9. Illes, A.
  10. de la Serna, J.
  11. Dolan, S.
  12. Campbell, P.
  13. Musuraca, G.
  14. Jacob, A.
  15. Avery, E.
  16. Lee, J.H.
  17. Liang, W.
  18. Patel, P.
  19. Quah, C.
  20. Jurczak, W.
Aldizkaria:
Journal of Clinical Oncology

ISSN: 1527-7755 0732-183X

Argitalpen urtea: 2020

Alea: 38

Zenbakia: 25

Orrialdeak: 2849-2861

Mota: Biltzar ekarpena

DOI: 10.1200/JCO.19.03355 GOOGLE SCHOLAR